Company / Cash & Equivalents
ImageneBio, Inc. Cash & Equivalents History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$94.5M
FY2025
5-year range
$39.4M / $232.2M
FY2021-FY2025
Trend
+140.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 5 years, ranging from $39M in FY2024 to $232M in FY2021.
Based on SEC 10-K filings.
$95M in FY2025 with a 3-year CAGR of +16.4%.
Declined from $120M to $95M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +16.4%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +16.4%, indicating consistent growth.
- In FY2025, cash & equivalents increased 140.0% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
- Lowest cash & equivalents in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $94.5M | +140.0% |
| FY2024 | $39.4M | -67.1% |
| FY2023 | $119.9M | +100.1% |
| FY2022 | $59.9M | -74.2% |
| FY2021 | $232.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026